Patents by Inventor Jinhua QIN

Jinhua QIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mobile terminal
    Patent number: 11929775
    Abstract: A mobile terminal, includes a housing, and a middle frame and a display that are disposed in the housing. The display is coupled to the middle frame. An accommodation space is formed between the display and the middle frame. In addition, the mobile terminal further includes a first magnet and a second magnet, and a part of the first magnet and a part of the second magnet are disposed in the accommodation space. The first magnet is disposed on a back facet of the display, the second magnet is disposed on the middle frame, and the first magnet and the second magnet are disposed face to face.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 12, 2024
    Assignee: HUAWEI TECHNOLOGIES CO., LTD.
    Inventors: Zhuojun Yu, Jinhua Liu, Yingming Li, Yuqing Zhang, Chien Feng Yeh, Renxuan Qin
  • Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application
    Patent number: 11149253
    Abstract: Provided are a small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, a reprogramming method and an application. Human gastric epithelial cells (hGECs) are used as initiating cells, human gastric subepithelial myofibroblasts (aGSEMFs) are used as a trophoblast, a compound combination having all or a plurality of FBP, Bay K 8644, Bix01294, SB431542 or A813-01, VPA, RG108, PD0325901 and PS48 including SB or A83 is used to reprogram digestive tract derived epithelial cells to endodermal stem/progenitor cells, and the endodermal stem/progenitor cells can be used for inducing differentiation towards liver cells, pancreatic beta cells and intestinal cells.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: October 19, 2021
    Assignee: INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA
    Inventors: Yunfang Wang, Shuyong Wang, Wencheng Zhang, Jinhua Qin, Xuan Wang, Mingyang Chang, Fang Yan, Xuetao Pei
  • SMALL MOLECULE COMPOUND COMBINATION FOR REPROGRAMMING DIGESTIVE TRACT DERIVED EPITHELIAL CELLS TO ENDODERMAL STEM/PROGENITOR CELLS, REPROGRAMMING METHOD AND APPLICATION
    Publication number: 20200385682
    Abstract: Provided are a small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, a reprogramming method and an application. Human gastric epithelial cells (hGECs) are used as initiating cells, human gastric subepithelial myofibroblasts (aGSEMFs) are used as a trophoblast, a compound combination having all or a plurality of FBP, Bay K 8644, Bix01294, SB431542 or A813-01, VPA, RG108, PD0325901 and PS48 including SB or A83 is used to reprogram digestive tract derived epithelial cells to endodermal stem/progenitor cells, and the endodermal stem/progenitor cells can be used for inducing differentiation towards liver cells, pancreatic beta cells and intestinal cells.
    Type: Application
    Filed: May 27, 2017
    Publication date: December 10, 2020
    Inventors: Yunfang WANG, Shuyong WANG, Wencheng ZHANG, Jinhua QIN, Xuan WANG, Mingyang CHANG, Fang YAN, Xuetao PEI